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Abstract Human epidermal growth factor receptor 2
(HER2) plays an important role in breast cancer progres-
sion and provides predictive information for response to
targeted therapy including trastuzumab although this is
limited. Downstream pathways, such as PI3K/Akt, are
associated with HER2/HER3 heterodimerization promot-
ing survival and proliferation amongst cancer cells. Thus,
patient outcome and trastuzumab therapy effectiveness
might be further characterised by HER2/HER3 dimerisa-
tion and its signalling pathways. HER2/HER3 dimerisation
status was assessed, using chromogenic in situ Proximity
Ligation Assay, in two breast cancer series: early stage
primary breast cancer, including 224 HER2? patients that
were not submitted to trastuzumab, and HER2? breast
cancer where patients were treated with adjuvant trast-
uzumab (n = 143). Levels of biomarkers including PI3K,
pAKT, ER, PgR, HER3, BCL2, p53, PTEN and p21 were
measured using immunohistochemistry. Levels of HER2/
HER3 heterodimers were compared with biomarker
expression and patient outcome. An association between
high levels of HER2/HER3 dimerisation and absence of
hormone receptors, ER and PgR, was observed. We further
show for the first time the presence of HER2/HER3 het-
erodimers and the loss of p21 expression in HER2? breast
cancer predicts a significantly poorer outcome when sub-
mitted to adjuvant trastuzumab. Breast cancer patients that
reveal high levels of HER2/HER3 dimerisation and loss of
p21 are associated with poor survival prognosis in patients
with HER2? breast cancer treated with adjuvant trast-
uzumab. Further quantification analysis of HER dimer/
ligand complexes and downstream signalling pathways will
begin to unravel the complex associations with patient
outcome and its relationship with sensitivity to targeted
treatment.
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Introduction
Breast cancer cases exhibiting overexpression of human
epidermal growth factor receptor 2 (HER2) are correlated
with poor patient survival [1–3]. HER family comprise
four members, EGFR, HER2, HER3 and HER4 [4], which
are part of the Type I group of receptor tyrosine kinases
(RTKs) which have an important role regulating cell
metabolism including migration, survival, adhesion, dif-
ferentiation and proliferation [5, 6]. However, HER2 and
HER3 are not able to stimulate cell signalling as mono-
mers as HER2 does not possess an ectodomain competent
for interaction with any ligand, whereas HER3 lacks the
kinase complex [7]. In order to activate downstream sig-
nalling cascades, it is compulsory that cooperation
between these two receptors occurs resulting into an active
heterodimer [8].
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The frequency of HER2 overexpression is 13–23 % in
breast cancer and is associated with hormone receptor
negative disease and thus associated with a poor prognosis
[2, 4, 9] due to its aggressive behaviour and metastatic
potential. [1, 3, 10]. Downstream pathways activated by
overexpression of HER2 [11], include the RAS-MAPK
pathway promoting proliferation, and the PI3K/Akt path-
way resulting in apoptosis avoidance [7], angiogenesis
[12], phospholipase Cc and signal transducer and activa-
tion of transcription (STATs) proteins [13].
HER3 is overexpressed in 10–30 % of breast cancer and
is also associated with poor prognosis [4]. The absence of
an activated tyrosine kinase domain is explained by the
possession of mutations on four amino acids resulting in
tyrosine low activity and the obligation of dimerisation to
trigger the signalling cascade [14, 15]. In breast carcinoma,
the levels of HER3 can increase significantly when com-
pared with normal cells due to overexpression, possibly
instigated by protein translation or higher molecule half-
life [16]. HER3 expression in breast cancer is highly
associated with anti-apoptosis development by promotion
of the PI3K signalling pathway [17].
Moreover, cell transformation and breast carcinoma pro-
gression might be triggered by HER2 and HER3 interaction
[16] as this is the most common heterodimer associated with
proliferative downstream pathways [15]. Therefore, the het-
erodimer HER2/HER3 could be essential to sustain a con-
stitutive role of the PI3K downstream pathway [18].
HER2? breast cancer patients are submitted to targeted
therapy including trastuzumab (HerceptinTM; Genentech;
South San Francisco, CA). While trastuzumab interacts
with HER2, the mechanism of action remains ill-defined.
Despite the predictive value of HER2 positivity, only 35 %
of patients with HER2? metastatic breast cancer show
response when submitted to trastuzumab alone [19].
However, when trastuzumab is applied with first-line che-
motherapy, the levels of success can increase up to 84 %
[20, 21]. Therefore, alternative mechanisms that are not
disturbed by trastuzumab alone might be implicated in
carcinoma expansion [22]. Moreover, trastuzumab might
be effective at initial treatments, however, after a period
resistance increases substantially [23], even though the
overall survival time might be expanded if a combination
with chemotherapy takes place [24, 25].
We have previously used chromogenic in situ proximity
ligation assay (PLA) to quantify and characterise the expression
of HER2/HER3 heterodimers in a large series of breast cancers
which showed that HER2/HER3 heterodimers were detected in
13.1 % of all breast cancers and 73 % of HER2? tumours [26].
While HER2/HER3 dimers were associated with proliferation,
distant metastasis and poor patient outcome, it did not dis-
criminate divergent outcomes within HER2? breast cancer or
predict response to trastuzumab.
Therefore, in this study, we have further characterised
HER2/HER3 dimerisation and investigated its association
with the relevant pathways to increase our understanding of
this complex system of cross-talk between receptors and




Primary breast cancer series (unselected series)
The patient series comprised 1,858 unselected primary
operable invasive breast carcinoma cases, presenting
between 1986 and 1998, from the well-characterised Not-
tingham-Tenovus primary breast carcinoma series [27–29].
Clinicopathological parameters for this series are summa-
rised in Table 1.
HER2? trastuzumab naı¨ve series
The HER2? trastuzumab naı¨ve series (n = 224) was
composed by all HER2 positive cases part of unselected
series. Clinicopathological parameters for this series are
summarised in Table 1.
Biological characterisation, including immunoreactivity,
marking and categorising of ER, progesterone receptor
(PgR), and Triple Negative Phenotype (TN) were delin-
eated in there series as previously described [30–33].
HER2? adjuvant trastuzumab series
The HER2? adjuvant trastuzumab series consisted of 143
primary operable breast tumours from patients presenting
between 2003 and 2010 who received adjuvant trast-
uzumab. Clinicopathological parameters for this series are
summarised in Table 1.
HER2? series
Combining the HER2? adjuvant trastuzumab and
HER2? trastuzumab naı¨ve series resulted in the HER2?
series, which included 367 patients. Clinicopathological
parameters for this series are summarised in Table 1.
Immunohistochemistry and chromogenic in situ
hybridisation
TMAs were prepared as previously described [30].
Immunohistochemistry was performed using novolink
polymer detection systems (Leica) using primary
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antibodies (Table 2). TMA sections were counterstained
with Mayer’s haematoxylin.
Immunoreactivity of HER2 in TMA cores was scored
using standard HercepTest guidelines (Dako). Chromo-
genic in situ Hybridisation (CISH) was used to quantify
HER2 gene amplification using the HER2 FISH phar-
mDxTM plus HER2 CISH pharmDxTM kit (Dako) as pre-
viously described [26]. HER2 classification was assessed
by using American Society of Clinical Oncology guide-
lines as previously described [26].
The expression of biomarkers were evaluated by
assessing percentage staining and H-score [34]. Only
invasive cancer cells localised within tissue cores were
considered and only cores exhibiting at least 15 % of
tumour cells were scored. TMAs were scored using high-
resolution digital images (NanoZoomer; Hamamatsu Pho-
tonics), at 920 magnification, using a web-based interface
(Distiller; Slidepath Ltd.).
The REMARK guidelines were followed in the experi-
mental procedures [35].
Table 1 Clinicopathological characteristics of the unselected series (n = 1,858), HER2? trastuzumab naı¨ve series (n = 224), HER2? adjuvant
trastuzumab series (n = 143) and HER2? Series (n = 367)
Characteristics Unselected series HER2? (trastuzumab naı¨ve) HER2? (adjuvant trastuzumab) HER2? (naı¨ve ? adjuvant)
n (%) n (%) n (%) n (%)
Age at diagnosis (years)
\50 601 (32.4) 82 (36.6) 61 (43.6) 143 (39.3)
C50 1,256 (67.6) 142 (63.4) 79 (56.4) 221 (60.7)
Menopausal
Pre 700 (37.7) 92 (41.1) 26 (18.6) 118 (32.4)
Post 1,154 (62.3) 132 (58.9) 114 (81.4) 246 (67.6)
Death
No 1,043 (68.3) 98 (50.3) 133 (93.0) 231 (68.3)
Yes 483 (31.7) 97 (49.7) 10 (7.0) 107 (31.7)
Tumour size (cm)
\1.5 484 (26.1) 38 (17.0) 23 (16.1) 61 (16.6)
C1.5 1,367 (73.9) 186 (83.0) 120 (83.9) 306 (83.4)
Tumour grade
1 354 (19.1) 5 (2.2) 3 (2.1) 8 (2.2)
2 616 (33.3) 33 (14.8) 37 (25.9) 70 (19.1)
3 880 (47.6) 186 (83.0) 103 (72.0) 289 (78.7)
Lymph node Stage
1 1,187 (64.1) 122 (54.8) 53 (37.3) 178 (47.9)
2 505 (27.3) 67 (30.0) 56 (39.4) 123 (33.7)
3 159 (8.6) 34 (15.2) 33 (23.2) 67 (18.4)
Distant metastasis
No 1,288 (69.7) 122 (54.5) 124 (87.9) 246 (67.4)
Yes 559 (30.3) 102 (45.5) 17 (12.1) 119 (32.6)
Vascular invasion
Negative 1,061 (58.2) 118 (53.4) 79 (56.0) 197 (54.4)
Positive 763 (41.8) 103 (46.6) 62 (44.0) 165 (45.6)
Relapse
No 1,093 (60.4) 108 (48.9) 119 (83.9) 227 (62.5)
Yes 718 (39.6) 113 (51.1) 23 (16.1) 136 (38.5)
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In situ proximity ligation assay (PLA)
Quantification of HER heterodimers was measured using
in situ PLA for brightfield microscope as per the manu-
facturer’s instructions (Duolink kit, Olink) as previously
described [26]. 4 lm TMA sections were mounted on
X-traTM adhesive micro slide (Surgipath, Leica). Depar-
affinization was performed, and heat-induced antigen
retrieval was executed for 20 min in citrate buffer (pH 6.0).
Endogenous peroxidase was quenched using 0.3 %
hydrogen peroxide for 5 min and followed by a blocking
solution for 30 min at 37 C. To detect heterodimers, target
antibodies from two different species were applied at pre-
viously determined optimal conditions. The anti-HER2
rabbit antibody (Dako, 1:200) and anti-HER3 mouse anti-
body (clone 2F12, Neomarkers, 1:40) were used, and
incubated together for 30 min at room temperature (RT).
This was followed by incubation with the PLA probe in a
pre-heated humidity chamber for 90 min at 37 C.
Hybridisation/ligation incubation took place for 30 min
and amplification for 120 min at 37 C. To detect
hybridisation, Horse Radish Peroxidase was used and
incubated for 30 min at RT followed by appliance of
substrate solution for 10 min at RT. Counterstaining was
performed using Duolink nuclear staining for 2 min at RT
followed by washing the slides under running tap water for
10 min. Slides were mounted with a coverslip after dehy-
dration of the sections.
Image analysis
To quantify the HER2/HER3 heterodimers, image analysis
was employed using Duolink ImageTool (Olink, Swe-
den). High-resolution images of TMA sections were
acquired at 940 magnification (NanoZoomer).
One observer (FFTB) scored all IHC and PLA results,
which were rescored arbitrarily revealing a high concor-
dance between both occasions.
Statistical analysis
All statistical analyses were performed using SPSS 19.0
(SPSS Inc., Chicago, Illinois). Pearson’s v2 association
analysis was employed in support of inter-relationships
between HER2/HER3 dimerisation occurrence status with
clinicopathological parameters, and biomarkers. For any
relationship to be considered significant, a p value of\0.05
was used.
Ethics
Nottingham Research Ethics Committee 2 approved this
research project under the title of ‘Development of a
molecular genetics classification of breast cancer.’
Results
HER2/HER3 heterodimers and correlation
with biomarkers
Table 3 summarises the correlations between HER2/HER3
dimer levels and biomarkers of importance in breast can-
cer. In the unselected series, a significant positive corre-
lation was observed between high levels of HER2/HER3
heterodimer expression with pAkt (p = 0.044), PI3K
(p \ 0.001), p53 (p \ 0.001) and PTEN (p = 0.006).
There was a negative association between HER2/HER3
heterodimer expression and Bcl-2, BRCA1 (p = 0.005),
ER, PgR (all p \ 0.001) and MUC-1 (p = 0.020).
Within the HER2? series, there were similar correla-
tions but an association with p21 (p = 0.027) and lack of
correlation with PTEN and p53 were observed.
Table 2 Dilution, Source and pretreatment of antibodies used on
both immunohistochemistry and in situ proximity ligation assay and
the cut-off used to classify each biomarker





ER [SP1] 1:50 30 Dako 0
PgR [PgR 636] 1:125 30 Dako 0
Human epidermal growth factor receptor proteins





1:20 30 Dako 10
CK14 [LL002] 1:100 30 Novocastra 10
Cell Cycle associated proliferation and apoptosis related proteins
Ki67 [MB-1] 1:100 30 Dako 10–50a
PI3K 1:50 60 Sigma
Aldrich
30–100a
AktpS473 [14–5] 1:10 30 Dako 60a
P21 [SX118] 1:100 30 Dako 0
Bcl-2 [124] 1:100 30 Dako 30
Tumour suppressor genes
PTEN [6H2.1] 1:100 60 Dako 10–100a
P53 [DO7] 1:50 30 Novocastra 5
BRCA1
[MS110]




1:350 30 Novocastra 20–200a
a H-score
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Representative tumours showing HER2/HER3 hetero-
dimers and p21 expression are shown in Fig. 1.
Association of HER2/HER3 heterodimers with patient
outcome
HER2/HER3 heterodimers were associated with poor
patient outcome (BCSS and DFI) in the unselected series
but not in the HER2? naı¨ve or HER2? trastuzumab series
(Fig. 2). Kaplan–Meier survival analyses showed that
BCSS and DFI outcome of those cases submitted to
adjuvant trastuzumab treatment against trastuzumab naı¨ve
patients which revealed a significantly better patient out-
come in patients receiving trastuzumab (p \ 0.001, data
not shown).
Further analysis showed that amongst the ER-positive
population in the unselected series, high HER2/HER3 di-
merisation was significantly associated with shorter BCSS
and DFI in both the short (5 years) and long (maximum
Table 3 Association of HER2/HER3 dimerisation levels with biomarker expression in breast cancer
HER2/HER3 Status
Biomarker Unselected series HER2? series
Low (%) High (%) p value (v2) Low (%) High (%) p value (v2)
Bcl-2
Negative 207 (41.0) 53 (75.7) <0.001 (29.925) 32 (47.1) 80 (66.1) 0.010 (6.549)
Positive 298 (59.0) 17 (24.3) 36 (52.9) 41 (33.9)
pAkt
Negative 121 (25.4) 11 (15.5) 0.044 (3.295) 11 (29.7) 11 (19.6) 0.263 (1.255)
Positive 356 (74.6) 60 (84.5) 26 (70.3) 45 (80.4)
PI3K
Negative 122 (22.1) 7 (8.6) <0.001 (15.942) 4 (5.8) 5 (3.7) 0.105 (4.512)
Moderate 143 (25.9) 13 (16.0) 12 (17.4) 11 (8.2)
Strong 288 (52.0) 61 (75.3) 53 (76.8) 118 (88.1)
p21
Negative 99 (79.2) 10 (90.9) 0.351 (0.871) 17 (45.9) (2.9) 12 (23.5) 0.027 (4.877)
Positive 26 (20.8) 1 (9.1) 20 (54.1) 39 (76.5)
MUC-1
Negative 69 (12.9) 2 (2.6) 0.020 (7.834) 4 (5.6) 4 (3.1) 0.581 (0.581)
Moderate 243 (45.3) 43 (56.6) 39 (54.9) 66 (52.0)
Strong 224 (41.8) 31 (40.8) 28 (39.4) 57 (44.9)
BRCA1
Negative 317 (61.0) 59 (77.6) 0.005 (7.913) 48 (72.7) 85 (69.1) 0.603 (0.270)
Positive 203 (39.0) 17 (22.4) 18 (27.3) 38 (30.9)
p53
Negative 435 (71.7) 46 (48.9) <0.001 (19.524) 27 (36.0) 45 (31.5) 0.499 (0.457)
Positive 172 (28.3) 48 (51.1) 48 (64.0) 98 (68.5)
PTEN
Weak 79 (22.8) 3 (5.5) 0.006 (10.092) 0 (0.0) 5 (5.7) 0.265 (2.653)
Moderate 130 (37.5) 21 (38.2) 21 (53.8) 40 (45.5)
Strong 138 (39.8) 31 (56.4) 18 (46.2) 43 (48.9)
ER
Negative 169 (28.3) 56 (60.2) <0.001 (37.424) 23 (31.1) 91 (62.8) <0.001 (19.699)
Positive 429 (71.7) 37 (39.8) 51 (68.9) 54 (37.2)
PgR
Negative 264 (44.2) 65 (70.7) <0.001 (22.321) 36 (48.6) 100 (71.4) 0.001 (10.845)
Positive 333 (55.8) 27 (29.3) 38 (51.4) 40 (28.6)
Bold values indicate significant values (p \ 0.005)
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26 years, median 11 years) term (Fig. 3). A multivariate
Cox regression model, including tumour size, tumour stage
and tumour grade, revealed that high levels of HER2/HER3
amongst the ER-positive patients were independently
associated with worse BCSS (HR = 0.46, 95 % CI
0.29–0.74, p = 0.001, Table 4) but not with DFI
(HR = 0.67, 95 % CI 0.43–1.06, p = 0.087). There was no
correlation between HER2/HER3 heterodimer and patient
outcome in the ER-negative population of the unselected
series for both short- and long-term BCSS (Fig. 3). There
Fig. 1 p21and HER2/HER3
heterodimer expression in two
HER2 ? breast tumours. p21
expression: a, low and b, high at
109 magnification. HER2/
HER3 heterodimer expression:
High expression (c, 109
magnification; e, 409
magnification) and low
expression (d, 10 9 21
magnification; f, 409
magnification)
cFig. 2 BCSS and DFI analysis for HER2/HER3 heterodimer status.
Unselected series (a, b), trastuzumab Naı¨ve Series (c, d) and
trastuzumab adjuvant series (e, f)
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was likewise no association with BCSS in either ER-
positive or ER-negative expression with high levels of
HER2/HER3 heterodimers in the HER2? naı¨ve or trast-
uzumab series.
In the HER2? trastuzumab series, there was a signifi-
cantly better overall survival of patients who had high levels
of HER2/HER3 dimersation but were negative for p21
expression compared with patients who were either p21
positive or did not have HER2/HER3 dimerisation
(p = 0.001, Fig. 4a). A similar observation was made with
disease-free interval (p = 0.015, Fig. 4b). There were no
other associations in the HER2? trastuzumab or naı¨ve series
Fig. 3 HER2/HER3 heterodimer expression in unselected breast cancer and patient outcome. ER positive (a, b) and ER negative (c, d) tumours
for BCSS and DFI
Table 4 Multivariate Cox
regression analysis of factors
associated with BCSS and DFI
for ER-positive cases in the
unselected series
Variable BCSS DFI
Hazard ratio (95 % CI) p value Hazard ratio (95 % CI) p value
Tumour size (cm) 0.48 (0.28–0.85) 0.011 0.57 (0.38–0.85) 0.007
Tumour stage 1.69 (1.33–2.16) \0.001 1.61 (1.30–1.99) \0.001
Tumour grade 1.77 (1.37–2.30) \0.001 1.22 (0.99–1.49) 0.059
HER2/HER3 heterodimer 0.46 (0.29–0.74) 0.001 0.67 (0.43–1.06) 0.087
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with either OS or PFS between HER2/HER3 heterodimers
and the other biomarkers investigated in this study.
Discussion
HER2/HER3 heterodimers have been described as to be
the major interaction in HER2-amplified breast carcino-
mas [36]. We and others have observed that
approximately 70 % of all HER2? tumours demonstrate
HER2/HER3 heterodimers [26, 37]. Where HER3 inter-
acts with HER2, downstream pathways responsible for
proliferation and survival are triggered [38], also stimu-
lating creation of metastases [39]. Therefore, in this study,
chromogenic PLA was utilised to detect HER2/HER3
dimerisation levels in archival primary formalin-fixed
breast carcinomas including HER2? breast cancer, either
receiving only chemotherapy or adjuvant trastuzumab and
chemotherapy. Investigating HER2/HER3 dimers, along
with downstream targets using IHC, aimed to improve
and provide further detailed information of the biology of
HER2? disease and the mechanisms of targeted treat-
ments and resistance.
HER2/HER3 develops an important role in promotion of
cell proliferation and apoptosis avoidance [40]. Even
though HER2/HER3 heterodimers were not associated with
the cell proliferation marker, Ki67 [41] it was negatively
associated with Bcl-2, which is highly correlated with
apoptosis avoidance [42]. As a monomer, HER2 is not
competent of interacting with PI3K subsequently activating
the PI3K/Akt pathway. However, the HER2/HER3 het-
erodimer is favourably efficient performing it, which was
confirmed by the strong association with both Akt and
PI3K expression. This role is stimulated by HER3 that
contains six tyrosine-binding points with the highest
affinity for PI3 K amongst the HER family [17, 43, 44].
Therefore, instigation of HER3 results in a durable and
strong trigger of the downstream PI3 K/Akt cascade [45].
Additionally, the high association of HER2/HER3 hetero-
dimers with CK18 supports the idea that apoptosis does not
take place amongst these cells due to CK18 high levels of
degradation being associated with apoptosis [46, 47].
HER2/HER3 was also associated with strong levels of
MUC-1, which is associated with poor prognosis amongst
the breast cancer patients being described to be connected
with the metastases progression process [48, 49].
Interestingly, it was observed that low HER/HER3 di-
merisation levels were associated with ER and PR posi-
tivity. This fact is in concordance to those studies
suggesting an absence of HER2 overexpression when
hormone receptors are present in cancer cells [10, 50]. The
high association between ER and BCL-2 is already docu-
mented [42] and observed in this study which might
explain the poor outcome observed amongst those patients
revealing high levels of HER2/HER3 and ER? status.
Moreover, the multivariate analysis revealed HER2/HER3
high levels as an independent prognostic factor for both
BCSS and DFI. This finding is in concordance to the pre-
vious study [51], supporting the idea that this protein–
protein interaction may deliver additional prognostic
information to that obtained by HER2 gene amplification
status. For those patients with negative ER status, no
Fig. 4 Patient outcome with respect to HER2/HER3 and p21 status
in HER2? breast cancer treated with trastuzumab. Overall survival
(a) and disease-free interval (b). HER2/HER3 ? p21- (n = 13),
Other groups: HER2/HER2 ? p21 ? , HER2/HER3- p21 ? , HER2/
HER3-p21- (n = 75). Time in months
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significant difference was observed regarding HER2/
HER3. This indicates an inverse association between the
dimerisation status and the expression of the hormone
receptors, supporting the idea of a negative regulation of
HER2 in the presence of hormone receptors [52], even
though it can be partially reversible [50].
We have previously shown that the presence of HER2/
HER3 heterodimers alone did not reveal a significant
prognostic prediction in HER2? breast cancer treated with
adjuvant trastuzumab [26]. We show for the first time, the
presence of HER2/HER3 heterodimers and the loss of p21
expression in HER2? breast cancer predict a significantly
poorer outcome when submitted to adjuvant Trastuzumab.
Trastuzumab has been shown to interfere HER2? intra-
cellular signalling by inhibiting DNA damage repair,
inducing cell cycle arrest and inhibiting tumour angio-
genesis. There is conflicting in vitro data whether Trast-
uzumab directly affects DNA damage repair modulated by
p21. A study by Pietras et al. [19] showed that it decreased
p21 expression thereby promoting DNA damage, whereas
another study showed little change in p21 levels [53].
However, there is stronger evidence that HER2 amplifica-
tion or Trastuzumab promotes the cellular localisation of
p21 thereby affecting the inhibition of cell proliferation
[53–55], although in the current study, only nuclear p21
expression was taken into account.
In conclusion, loss of p21 expression mediated through
HER2/HER3 heterodimerization is associated with poor
outcome in patients with HER2? breast cancer treated with
adjuvant Trastuzumab. Incorporating further analysis in a
larger series with longer follow-up is most likely to assist in
qualifying this hypothesis. Additionally, characterisation of
the ligands amongst HER2? breast cancer is urgently
required to create a more robust classification method in
order to avoid high levels of unsuccessfully therapy.
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